Evidence mapPaperPMID 38969729Full record

ArticleScientific reports2024

Enhanced anticancer activity of silver doped zinc oxide magnetic nanocarrier loaded with sorafenib for hepatocellular carcinoma treatment.

Doaa S R Khafaga, M M Eid, Mona H Mohamed, Mohamed D E Abdelmaksoud, Mie Afify, Ahmed M El-Khawaga, Heba K Abdelhakim

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Doaa S R KhafagaBiochemistry Division, Faculty of Science, Cairo University, Giza, 12613, Egypt. doaa.rashwan@gu.edu.eg.
M M EidSpectroscopy Department, National Research Centre, Dokki, Cairo, Egypt.
Mona H MohamedDepartment of Chemistry, Faculty of Science, Cairo University, Giza, 12613, Egypt.
Mohamed D E AbdelmaksoudBiochemistry Department, Biotechnology Research Institute, National Research Centre, Cairo, Egypt.
Mie AfifyBiochemistry Department, Biotechnology Research Institute, National Research Centre, Cairo, Egypt.
Ahmed M El-KhawagaDepartment of Basic Medical Sciences, Faculty of Medicine, Galala University, New Galala City, Suez, 43511, Egypt. Ahmed.Elkhawaga@gu.edu.eg.
Heba K AbdelhakimBiochemistry Division, Faculty of Science, Cairo University, Giza, 12613, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug delivery is the process or method of delivering a pharmacological product to have therapeutic effects on humans or animals. The use of nanoparticles to deliver medications to cells is driving the present surge in interest in improving human health. Green nanodrug delivery methods are based on chemical processes that are acceptable for the environment or that use natural biomaterials such as plant extracts and microorganisms. In this study, zinc oxide-superparamagnetic iron oxide-silver nanocomposite was synthesized via green synthesis method using Fusarium oxysporum fungi mycelia then loaded with sorafenib drug. The synthesized nanocomposites were characterized by UV-visibile spectroscopy, FTIR, TEM and SEM techniques. Sorafenib is a cancer treatment and is also known by its brand name, Nexavar. Sorafenib is the only systemic medication available in the world to treat hepatocellular carcinoma. Sorafenib, like many other chemotherapeutics, has side effects that restrict its effectiveness, including toxicity, nausea, mucositis, hypertension, alopecia, and hand-foot skin reaction. In our study, 40 male albino rats were given a single dose of diethyl nitrosamine (DEN) 60 mg/kg b.wt., followed by carbon tetrachloride 2 ml/kg b.wt. twice a week for one month. The aim of our study is using the zinc oxide-superparamagnetic iron oxide-silver nanocomposite that was synthesized by Fusarium oxysporum fungi mycelia as nanocarrier for enhancement the sorafenib anticancer effect.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsSilverSorafenibZinc OxideAnimalsDrug CarriersFusariumHumansMagnetic Iron Oxide NanoparticlesMagnetite NanoparticlesMaleNanocompositesRatsAntineoplastic AgentsDrug CarriersMagnetite NanoparticlesSilverSorafenibZinc OxideDiethyl nitrosamineDrug deliveryHepatocellular carcinomaNanocompositeSorafenibZinc oxide

Identifiers

PMID38969729
PMCPMC11226637

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.